Ascendis Pharma A/S $ASND Stock: Morse Asset Management Inc Boosts Position

Morse Asset Management Inc lifted its position in Ascendis Pharma A/S (NASDAQ:ASND – Free Report) by 27.3% in the 3rd quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 12,210 shares of the biotechnology company’s stock after acquiring an additional 2,621 shares during the period. Morse Asset Management Inc’s holdings in Ascendis Pharma A/S were worth $2,782,000 as of its most recent SEC filing.

Several other institutional investors have also recently made changes to their positions in ASND. EverSource Wealth Advisors LLC lifted its stake in shares of Ascendis Pharma A/S by 34.0% in the 1st quarter. EverSource Wealth Advisors LLC now owns 272 shares of the biotechnology company’s stock valued at $62,000 after purchasing an additional 69 shares during the period. Allworth Financial LP grew its stake in Ascendis Pharma A/S by 103.4% in the second quarter. Allworth Financial LP now owns 240 shares of the biotechnology company’s stock worth $64,000 after purchasing an additional 122 shares during the period. Fifth Third Bancorp grew its stake in Ascendis Pharma A/S by 48.4% in the third quarter. Fifth Third Bancorp now owns 279 shares of the biotechnology company’s stock worth $64,000 after purchasing an additional 91 shares during the period. Parallel Advisors LLC grew its stake in Ascendis Pharma A/S by 94.9% in the first quarter. Parallel Advisors LLC now owns 304 shares of the biotechnology company’s stock worth $70,000 after purchasing an additional 148 shares during the period. Finally, IFP Advisors Inc grew its stake in Ascendis Pharma A/S by 3,491.7% in the second quarter. IFP Advisors Inc now owns 431 shares of the biotechnology company’s stock worth $115,000 after purchasing an additional 419 shares during the period.

Wall Street Analysts Forecast Growth

A number of equities analysts have issued reports on ASND shares. Canaccord Genuity Group increased their price objective on Ascendis Pharma A/S from $268.00 to $274.00 and gave the stock a “hold” rating in a report on Friday. Weiss Ratings upgraded shares of Ascendis Pharma A/S from a “hold (c)” rating to a “hold (c+)” rating in a report on Friday. Royal Bank Of Canada set a $352.00 target price on shares of Ascendis Pharma A/S in a report on Friday. Citigroup reduced their target price on shares of Ascendis Pharma A/S from $360.00 to $330.00 and set a “buy” rating on the stock in a research report on Monday, October 26th. Finally, UBS Group upped their target price on shares of Ascendis Pharma A/S from $269.00 to $315.00 and gave the stock a “buy” rating in a research report on Friday. Nineteen analysts have rated the stock with a Buy rating and two have given a Hold rating to the company’s stock. According to data from MarketBeat, Ascendis Pharma A/S currently has a consensus rating of “Moderate Buy” and a consensus price target of $313.52.

Get Our Latest Analysis on Ascendis Pharma A/S

Trending Headlines about Ascendis Pharma A/S

Here are a few of the latest headlines about ASND:

  • Positive Sentiment: Q3 results and commercial growth were strong. Ascendis reported revenue of $418.7 million, above analyst expectations, while product revenue reached €366 million, up 89% year over year. YORVIPATH accounted for €291 million of product sales. The company also reported a quarterly profit, marking a shift toward commercial-scale profitability. Ascendis Pharma Q3 2026 results
  • Positive Sentiment: Analyst updates lean bullish. TD Cowen raised its target to $352 and UBS lifted its target to $315, both maintaining buy ratings. Cantor Fitzgerald also raised its target to $315 with an overweight rating; RBC reaffirmed outperform at $290. These higher targets indicate continued analyst confidence in the outlook. Read More. · Read More. · Read More. · Read More.
  • Neutral Sentiment: Analyst views are not unanimous. Canaccord raised its target to $274 but kept a hold rating, while HC Wainwright cut its target to $335, though it retained a buy rating. Read More. · Read More.

Insider Buying and Selling at Ascendis Pharma A/S

In related news, SVP Mads Bodenhoff sold 3,000 shares of the business’s stock in a transaction that occurred on Tuesday, September 8th. The shares were sold at an average price of $270.19, for a total value of $810,570.00. Following the completion of the transaction, the senior vice president directly owned 3,000 shares in the company, valued at $810,570. The trade was a 50.00% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 40.00% of the stock is owned by company insiders.

Ascendis Pharma A/S Price Performance

Shares of Ascendis Pharma A/S stock opened at $275.39 on Monday. The company has a debt-to-equity ratio of 0.25, a quick ratio of 2.29 and a current ratio of 2.89. The stock has a market capitalization of $17.18 billion, a PE ratio of 18.00 and a beta of 0.40. Ascendis Pharma A/S has a 52-week low of $188.08 and a 52-week high of $282.15. The company has a 50-day simple moving average of $242.67 and a two-hundred day simple moving average of $239.83.

Ascendis Pharma A/S (NASDAQ:ASND – Get Free Report) last issued its earnings results on Friday, August 14th. The biotechnology company reported $1.03 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.71 by ($0.68). The firm had revenue of $387.22 million during the quarter, compared to the consensus estimate of $376.75 million. Ascendis Pharma A/S had a return on equity of 32.47% and a net margin of 73.26%. On average, analysts anticipate that Ascendis Pharma A/S will post 3.43 EPS for the current fiscal year.

Ascendis Pharma A/S Company Profile

(Free Report)

Ascendis Pharma A/S is a biopharmaceutical company headquartered in Denmark that develops medicines for rare diseases, with a focus on endocrinology. Founded in 2006, the company uses its TransCon technology platform to design therapies intended to provide sustained delivery of medicines. Its commercial products include SKYTROFA (lonapegsomatropin), a once-weekly growth hormone treatment for children with growth hormone deficiency, and YORVIPATH (palopegteriparatide), a treatment for adults with hypoparathyroidism.

Recommended Stories

Want to see what other hedge funds are holding ASND? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Ascendis Pharma A/S (NASDAQ:ASND – Free Report).

Institutional Ownership by Quarter for Ascendis Pharma A/S (NASDAQ:ASND)

Receive News & Ratings for Ascendis Pharma A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ascendis Pharma A/S and related companies with MarketBeat.com's FREE daily email newsletter.